Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Atezolizumab in Urothelial Cancer
NCT04624399Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Jun 2021
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in urothelial carcinoma (UC), sponsored by Queen Mary University of London. Started Jun 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04624399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624399.